Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
GLP-1 Safety Knowledge: Student Survey
A Saudi pharmacy-student survey found a mean GLP-1 safety knowledge score of 7.6 out of 17, with a 26.5% response rate.
GLP-1 Use Before Bariatric Surgery
An editorial highlights a matched cohort linking prior GLP-1 or tirzepatide use with fewer early cardiorenal events after surgery.
Semax Glaucoma Cohort Readout
A 50-patient glaucoma surgery cohort found a visual-field signal with bundled physiotherapy, but it could not isolate an effect of Semax.
SLIM LIVER: Semaglutide and HIV
SLIM LIVER found improved liver-fat and blood-marker results with semaglutide in people with HIV, but the trial had no control group.
SURPASS-CVOT Beyond MACE
A 2026 commentary argues that SURPASS-CVOT may require endpoints beyond MACE, but its biological framework remains a hypothesis, not new trial evidence.
Tirzepatide With Biologics in PsA
A matched 2026 study linked concurrent tirzepatide and biologic initiation with better six-month outcomes in obese psoriatic arthritis.
Emerging knee OA therapies: review map
A 2026 review maps semaglutide, local GLP-1 candidates, gene therapy and other emerging knee osteoarthritis treatments.
GLP-1 drugs and dental evidence gaps
A 2026 appraisal found promising preclinical dental findings for GLP-1 drugs, but no prospective patient study with a dental endpoint.
Low-dose tirzepatide in older adults
A 28-week Japanese cohort found high persistence and modest metabolic change with low-dose tirzepatide in selected older adults.
Obesity and knee OA: what review found
A narrative review places semaglutide evidence inside broader weight-management care for people with obesity and knee osteoarthritis.
Oral semaglutide and needle phobia
A 2026 review examines oral semaglutide for people with needle phobia, but it reports no new head-to-head trial or adherence outcome.
Peptides in three dental nerve cases
Three dental nerve-injury cases improved during a multi-agent peptide intervention, but the uncontrolled report cannot establish efficacy.